文献速递药物不良反应与药物警戒特殊人群用药

基于CHPS与VBA的妇儿医院抗菌药物致血小板减少10年回顾性研究

A 10-year retrospective study of antibacterial-induced thrombocytopenia in a women and children hospital using China Hospital Pharmacovigilance System and Visual Basic for Applications.
PubMed 文献 · Br J Clin Pharmacol · 2024-04-10

AIMS: We aimed to investigate antibacterial-induced thrombocytopenia using the China Hospital Pharmacovigilance System (CHPS) in conjunction with Visual Basic for Applications (VBA).…

要点

  • 抗菌药物致血小板减少总发生率为0.46%,美罗培南1.77%、万古霉素1.55%、克林霉素0.44%。
  • 头孢他啶2.04%和哌拉西林/他唑巴坦1.24%分别为头孢菌素和青霉素类中最高。
  • 儿童较成人起病时间更长、血小板最低值更低且重症比例更高。

核心结论

  • 不同抗菌药物致血小板减少的发生率存在差异,儿童与成人在血小板减少特征上存在显著差异。

研究设计与样本

  • 2011年9月至2022年12月开展的10年回顾性研究,采用两阶段工作流程:CHPS算法初筛和经培训药师使用VBA进行因果关系评估。

主要发现

  • 药师使用VBA识别1039例(1246次抗菌药物治疗,28种药物)为潜在血小板减少事件(κ=0.89),发生率为0.46%。
  • 碳青霉烯类(美罗培南1.77%)、糖肽类(万古霉素1.55%)和林可酰胺类(克林霉素0.44%)为突出因果关系组。
  • 头孢菌素类和青霉素类中血小板减少发生率最高者分别为头孢他啶(2.04%)和哌拉西林/他唑巴坦(1.24%)。
  • 儿童较成人起病时间更长(61 vs. 29 h)、达最低值时间更长(83 vs. 37 h)、血小板最低值更低(110 vs. 92 × 109/L)、重症比例更高(12.37 vs. 3.86%)。

临床怎么用

  • 临床应关注碳青霉烯类、糖肽类、头孢他啶和哌拉西林/他唑巴坦等致血小板减少风险较高的抗菌药物。
  • 儿童患者使用抗菌药物时需更密切监测血小板变化,因其起病更晚、血小板最低值更低且重症比例更高。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: We aimed to investigate antibacterial-induced thrombocytopenia using the China Hospital Pharmacovigilance System (CHPS) in conjunction with Visual Basic for Applications (VBA). METHODS: Between September 2011 and December 2022, a 2-phase workflow was employed to identify antibacterial-induced thrombocytopenia, including preliminary screening in phase (I) conducted by CHPS algorithms and causality assessment by trained pharmacists in phase (II) using VBA. The incidence of thrombocytopenia in each antibacterial was calculated, and comparisons were performed between paediatric and adult patients. RESULTS: CHPS algorithms identified 4080 cases from 485 238 admissions (including 223 735 admissions receiving at least 1 antibacterial treatment). After ruling out cases with chemotherapy and abnormal platelet count at admission, 3832 cases were available. Using VBA, pharmacists identified 1039 cases (1246 antibacterial treatments, 28 agents) as potential thrombocytopenia instances (κ = 0.89), with an incidence of 0.46%. All antibacterial treatments correlated temporally with thrombocytopenia. Carbapenems (meropenem 1.77%), glycopeptides (vancomycin 1.55%) and lincosamides (clindamycin 0.44%) were prominent causal groups. The highest incidences of thrombocytopenia in the cephalosporins and penicillins groups were ceftazidime (2.04%) and piperacillin/tazobactam (1.24%), respectively. Among all antibacterial treatments, clindamycin showed the shortest time to onset (TTO), and erythromycin showed the longest TTO. Paediatric patients exhibited a longer TTO (61 vs. 29 h), extended time to nadir (83 vs. 37 h), lower platelet nadir count values (110 vs. 92 × 109/L), and a higher severe case proportion (12.37 vs. 3.86%) when compared with adults. CONCLUSION: Different antibacterial agents exhibit varying incidences of thrombocytopenia, with notable disparities between adults and children in the characteristics of thrombocytopenia.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Yang J, Cai C, Pan X, et al. A 10-year retrospective study of antibacterial-induced thrombocytopenia in a women and children hospital using China Hospital Pharmacovigilance System and Visual Basic for Applications. Br J Clin Pharmacol. 2024. PMID: 38600727. doi:10.1111/bcp.16041

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。